- Home
- PETZ vs PLUR Comparison
PETZ vs PLUR Comparison
Compare PETZ & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | PLUR |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 12.8M |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PETZ | PLUR |
|---|---|---|
| Price | $1.26 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.1K | ★ 12.2K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,016,000.00 |
| Revenue This Year | N/A | $902.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $0.85 |
| 52 Week High | $1.83 | $4.87 |
Technical Indicators
Market Signals| Indicator | PETZ | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 33.03 |
| Support Level | $1.11 | $0.90 |
| Resistance Level | $1.27 | $1.85 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 36.11 | 36.29 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.